IRCT20201225049827N1 IRCT 2021-02-16 Shahid Beheshti University of Medical Sciences Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin–A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder, Randomized Clinical Trial Study Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin–A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder, Randomized Clinical Trial Study 2021-02-03 anticipated 42 Complete https://irct.ir/trial/53817 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients who meet the inclusion criteria are simply randomized by computer software at the time of admission by someone who is not aware of the interventions. They are divided into two groups. Then an envelope containing the type of intervention that is not clear will be given to them and they will be referred to the operating room, Blinding description: The principal investigator, the health care personnel (physicians, nurses) who are responsible for patient care, the data collectors, and those who evaluate the outcome are blind and unaware of the patient's treatment process. The Data Protection and Supervision Committee is not aware. 3 LUTS In patients with benign prostatic hyperplasia. Intervention 1: Disport Botox injection of 300 mg diluted with 10 cc of normal saline is injected into the bladder detrusor once after transurethral resection of the prostate. Intervention 2: Control group: One month after transurethral resection of the prostate, they are treated with oral sulifenacin (vesicare 5mg) at a dose of 5 mg daily for 6 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information